Variability in Potency Among Commercial Preparations of Berberine
Open accessAbstract
Berberine is an isoquinoline alkaloid plant extract that is widely available as a dietary supplement in the United States and has demonstrated efficacy in the treatment of type 2 diabetes mellitus and dyslipidemia. Because of its increased use and purported pharmacological properties, potential variations in product quality could pose a barrier to berberine's safety and effectiveness in clinical practice. Thus, this study evaluated the potency of dietary supplements containing berberine available in the U.S. commercial market. Fifteen unique dietary supplements containing berberine were purchased through U.S. dietary supplement vendors. For each product, berberine was extracted from 3 unique capsules and analyzed by ultra-high-performance liquid chromatography tandem mass spectrometry. Percentage content based on the product label claim was determined for each product. The average berberine content across the products was found to be 75% ± 25% of the product label claim, with product potency ranging from 33% to 100%. Nine of the 15 tested products (60%) failed to meet the potency standards of 90% to 110% of labeled content claim, as commonly required of pharmaceutical preparations by the U.S. Pharmacopeial Convention. Evaluation of the relationship between product cost and the measured potency failed to demonstrate an association between quality and cost. Variability in product quality may significantly contribute to inconsistencies in the safety and effectiveness of berberine. In addition, the quality of the berberine product cannot be inferred from its cost.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Botanical identity and actual alkaloid content of berberine products vary considerably, and contamination and substitution are documented in botanical products.
“The first is product quality: botanical identity and actual alkaloid content vary considerably, and contamination and substitution are documented in botanical products [32,34].”
From Berberine-Drug Interactions: Mechanisms, Clinical Relevance and Risk Stratification-A Narrative Review (2026) · cites this paper as [32]
The Results (page not available in our copy) show considerable variation in actual berberine content across 15 products. The paper does not establish variation in botanical identity or document contamination or substitution; it measured berberine content, not those other aspects of product quality. (LLM, conf=0.89)
Experimental — accuracy not yet measuredNeither direction of product non-conformity can be read off the label, so the defensible position is that the perpetrator dose is unknown.
“Neither direction can be read off the label, so the defensible position is that the perpetrator dose is unknown [2,32,34].”
From Berberine-Drug Interactions: Mechanisms, Clinical Relevance and Risk Stratification-A Narrative Review (2026) · cites this paper as [32]
The Results report that tested berberine products contained 33%–100% of their labeled dose, supporting the point that a label may not reveal the actual dose. They do not document products exceeding the labeled amount, so this source does not support the claim about both directions of non-conformity. (LLM, conf=0.87)
Experimental — accuracy not yet measuredNon-conformity of a significant proportion of marketed berberine products means that the magnitude of any interaction is intrinsically unpredictable without standardization.
“Non-conformity of a significant proportion of marketed products means that the magnitude of any interaction is intrinsically unpredictable without standardization [32,34].”
From Berberine-Drug Interactions: Mechanisms, Clinical Relevance and Risk Stratification-A Narrative Review (2026) · cites this paper as [32]
The Abstract reports that 9 of 15 tested berberine products failed the stated potency standard, and the Discussion says potency variation may make clinical responses less predictable. The paper does not establish that the magnitude of drug interactions is intrinsically unpredictable without standardization; its Introduction notes only that berberine has the potential for clinically relevant interactions. Page numbers are not available in our copy. (LLM, conf=0.86)
Experimental — accuracy not yet measuredFormulations designed to raise absorption, whether TPGS-based, dihydroberberine or other enhanced-bioavailability preparations, change systemic exposure deliberately, so an effect size measured with one product cannot be carried over to another even when the labeled dose matches.
“Formulations designed to raise absorption, whether TPGS-based, dihydroberberine or other enhanced-bioavailability preparations, change systemic exposure deliberately, so an effect size measured with one product cannot be carried over to another even when the labeled dose matches.”
From Berberine-Drug Interactions: Mechanisms, Clinical Relevance and Risk Stratification-A Narrative Review (2026) · cites this paper as [32]
Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measuredThe heterogeneity of commercial products limits the generalizability of any effect-size estimate.
“Finally, the heterogeneity of commercial products limits the generalizability of any effect-size estimate [32,33].”
From Berberine-Drug Interactions: Mechanisms, Clinical Relevance and Risk Stratification-A Narrative Review (2026) · cites this paper as [32]
The Discussion (page unavailable) reports marked variation in berberine content among commercial products and says product-quality differences can produce inconsistent clinical responses. This supports concern about applying findings across products, but the paper does not assess the generalizability of effect-size estimates or establish that any such estimate is limited. (LLM, conf=0.83)
Experimental — accuracy not yet measured
Quantitative analysis of commercial berberine preparations found actual content deviating widely from the labeled amount.
“Quantitative analysis of commercial berberine preparations found actual content deviating widely from the labeled amount [32]”
From Berberine-Drug Interactions: Mechanisms, Clinical Relevance and Risk Stratification-A Narrative Review (2026) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Kong, W., Wei, J., Abidi, P., Lin, M., Inaba, S., Li, C., Wang, Y., Wang, Z., Si, S., Pan, H., et al. (2004) · Nature Medicine · doi:10.1038/nm1135 · Cited by 1,391 · see citing works
Why do patients turn to complementary medicine? An empirical study
Vincent, C. A., & Furnham, A. F. (1996) · British Journal of Clinical Psychology · doi:10.1111/j.2044-8260.1996.tb01160.x · Cited by 436 · see citing works
Pirillo, A., & Catapano, A. L. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.09.032 · Cited by 308 · see citing works
Application of Berberine on Treating Type 2 Diabetes Mellitus
Pang, B., Zhao, L., Zhou, Q., Zhao, T., Wang, H., Gu, C., & Tong, X. (2015) · International Journal of Endocrinology · doi:10.1155/2015/905749 · Cited by 254 · see citing works
Berberine decreases PCSK9 expression in HepG2 cells
Cameron, J., Ranheim, T., Kulseth, M. A., Leren, T. P., & Berge, K. E. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.02.004 · Cited by 232 · see citing works
Brown, A. C. (2017) · Food and Chemical Toxicology · doi:10.1016/j.fct.2016.11.001 · Cited by 184 · see citing works
Berberine and its derivatives: a patent review (2009 – 2012)
Singh, I. P., & Mahajan, S. (2012) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2013.746314 · Cited by 181 · see citing works
A clinician's guide to statin drug-drug interactions
Kellick, K. A., Bottorff, M. B., & Toth, P. P. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.02.010 · Cited by 162 · see citing works
Enerb�ck, L. (1974) · Histochemistry and Cell Biology · doi:10.1007/bf00492678 · Cited by 157 · see citing works
Berberine Activates GLUT1-Mediated Glucose Uptake in 3T3-L1 Adipocytes
Kim, S. H., Shin, E.-J., Kim, E.-D., Bayaraa, T., Frost, S. C., & Hyun, C. (2007) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.30.2120 · Cited by 136 · see citing works
Lu, S.-S., Yu, Y.-L., Zhu, H., Liu, X., Liu, L., Liu, Y.-W., Wang, P., Xie, L. Y., & Wang, G.-J. (2008) · Journal of Endocrinology · doi:10.1677/joe-08-0419 · Cited by 111 · see citing works
Berberine as a Promising Safe Anti-Cancer Agent- Is there a Role for Mitochondria?
Diogo, C. V., Machado, N. G., Barbosa, I. A., Serafim, T. L., Burgeiro, A., & Oliveira, P. J. (2011) · Current Drug Targets · doi:10.2174/138945011795528930 · Cited by 104 · see citing works
Dietary supplements: What's in a name? What's in the bottle?
Marcus, D. M. (2015) · Drug Testing and Analysis · doi:10.1002/dta.1855 · Cited by 97 · see citing works
Unmet Needs in LDL-C Lowering: When Statins Won’t Do!
Krähenbühl, S., Pavik-Mezzour, I., & von Eckardstein, A. (2016) · Drugs · doi:10.1007/s40265-016-0613-0 · Cited by 89 · see citing works
Dietary supplements quality analysis tools from the United States Pharmacopeia
Sarma, N. D., Giancaspro, G. I., & Venema, J. (2016) · Drug Testing and Analysis · doi:10.1002/dta.1940 · Cited by 64 · see citing works
Public safety and dietary supplementation
Gershwin, M. E., Borchers, A. T., Keen, C. L., Hendler, S. S., Hagie, F., & Greenwood, M. R. C. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05270.x · Cited by 55 · see citing works
Srinivasan, V. J. (2006) · Life Sciences · doi:10.1016/j.lfs.2005.12.014 · Cited by 35 · see citing works
Gershwin, M. E., & Greenwood, M. R. C. (2010) · Annals of the New York Academy of Sciences · Cited by 35 · see citing works
Dunnick, J. K., Singh, B., Nyska, A., Peckham, J., Kissling, G. E., & Sanders, J. M. (2011) · Toxicologic Pathology · doi:10.1177/0192623310394211 · Cited by 32 · see citing works
Pharmacologic Therapy of Type 2 Diabetes
Wright, J. J., & Tylee, T. S. (2016) · Medical Clinics of North America · doi:10.1016/j.mcna.2016.03.014 · Cited by 20 · see citing works
Zhang, Z., Li, Q., Li, Q., Du, S., Zhou, Y., Lv, C., Zhao, Y., Wang, Y., & Zhang, N. (2014) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2014.05.003 · Cited by 18 · see citing works
Haji, & Aminoddin (2011) · Cited by 16 · see citing works
An Ancient Chinese Herb Berberine; New Research in Diabetes Mellitus
Sha, W., Zhang, W., Huang, W., Zhou, M., Jingjing, N., Jiang, H., Junyan, L., Li, F., Zhu, T., Xin, X., et al. (2013) · International Journal of Integrative Medicine · doi:10.5772/56950 · Cited by 2 · see citing works
Flagged first, then by citations
Research works printed but not linked: 3
- Haji A, Iranian J Chem Chem Eng., 29, 55
- Pang B, Int J Endocrinol., 905749
- Sha W, Int J Integr Med., 1, 1
Cited by
Sorted by citations
A bird's eye view on a therapeutically ‘wonder molecule’: Berberine
Patel, P. K. (2021) · Phytomedicine Plus · doi:10.1016/j.phyplu.2021.100070 · Cited by 57 · see citing works
Wu, X., Li, X., Wang, W., Shan, Y., Wang, C., Zhu, M., Qiong, L., Zhong, Y., Xu, Y., Nan, P., et al. (2020) · BMC Genomics · doi:10.1186/s12864-020-07005-y · Cited by 48 · see citing works
Hilleman, D. E., Wiggins, B. S., & Bottorff, M. B. (2020) · Advances in Therapy · doi:10.1007/s12325-019-01211-1 · Cited by 46 · see citing works
Berberine in Human Oncogenic Herpesvirus Infections and Their Linked Cancers
Šudomová, M., Berchová‐Bímová, K., Marzocco, S., Líšková, A., Kubatka, P., & Hassan, S. T. S. (2021) · Viruses · doi:10.3390/v13061014 · Cited by 26 · see citing works
Martini, D., Pucci, C., Gabellini, C., Pellegrino, M., & Andreazzoli, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-73661-5 · Cited by 25 · see citing works
Zhu, C., Le, M., He, Z., Bai, Y., Yang, J. J., Ye, J., Chen, Z., & Jiang, Z. (2023) · Food & Function · doi:10.1039/d3fo01044a · Cited by 20 · see citing works
Targeting AMPK signaling: The therapeutic potential of berberine in diabetes and its complications
Mbara, K. C., Kheoane, P. S., & Tarirai, C. (2025) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2025.100689 · Cited by 17 · see citing works
Marcheluzzo, S., Faggian, M., Zancato, M., & Peron, G. (2021) · Molecules · doi:10.3390/molecules26082222 · Cited by 13 · see citing works
Berberine as a natural immunomodulator of B lymphocytes
Haftcheshmeh, S. M., Musavi, M., Lotfi, S., Soleimani, A., Dodangeh, M., Mohammadi, A., & Momtazi‐Borojeni, A. A. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01852-5 · Cited by 8 · see citing works
Quality evaluation of berberine food supplements with high-field and compact 1H NMR spectrometers
Danoun, S., Balayssac, S., Gilard, V., Martino, R., & Malet‐Martino, M. (2022) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2022.115161 · Cited by 6 · see citing works
A comprehensive compendium of berberine: sources, chemistry, and pharmacological activities
Mohapatra, N., Singh, T. G., Kumar, M. S., & Awasthi, A. (2025) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.70394 · Cited by 4 · see citing works
Berberine potentiates liver inflammation and fibrosis in the PI*Z hAAT transgenic murine model
Lu, Y., Mohammad, N. S., Lee, J., Aranyos, A. M., Serban, K. A., & Brantly, M. (2024) · PLoS ONE · doi:10.1371/journal.pone.0310524 · Cited by 4 · see citing works
Bürkle, F., Doll, J., Neide, A., Gantz, S., Tsitlakidis, S., & Fischer, C. A. (2022) · Journal of the International Society of Sports Nutrition · doi:10.1080/15502783.2022.2097018 · Cited by 3 · see citing works
Analysis of US Marketed Artemisinin Supplements for Use in Dogs
Berman, A. R., Birkenheuer, A. J., Sorah, E. L., & Papich, M. G. (2024) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/jvp.13480 · Cited by 3 · see citing works
Dumitru, C. N., Marcu, T., Dumitru, A. O., Tudor, S. S., Ferțu, I. D., Elisei, A.-M., & Goroftei, L. (2026) · Pharmaceuticals · doi:10.3390/ph19081313 · Cited by 2 · see citing works
“Neither direction can be read off the label, so the defensible position is that the perpetrator dose is unknown [2,32,34].”
InfluentialWu, X., Li, X., Wang, W., Shan, Y., Wang, C., Zhu, M., Qiong, L., Zhong, Y., Xu, Y., Nan, P., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13257684
Wu, X., Li, X., Wang, W., Shan, Y., Wang, C., Zhu, M., Qiong, L., Zhong, Y., Xu, Y., Nan, P., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13257681
Wu, X., Li, X., Wang, W., Shan, Y., Wang, C., Zhu, M., Qiong, L., Zhong, Y., Xu, Y., Nan, P., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13257693
Alkaloids: “Dope or Medication?”
Steinberg, C. E. W. (2025) · Springer eBooks · doi:10.1007/978-3-031-97988-0_4
Petrović, B. B., Radaković, M., Vukomanovic, V. A., Durutović, O., Nikolić, D. L., Nikolic, M. M., & Milosavljević, M. Z. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33152-7.00022-3
Wu, X., Li, X., Wang, W., Shan, Y., Wang, C., Zhu, M., La, Q., Zhong, Y., Xu, Y., Nan, P., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13257678
Wu, X., Li, X., Wang, W., Shan, Y., Wang, C., Zhu, M., La, Q., Zhong, Y., Xu, Y., Nan, P., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13257702
Wu, X., Li, X., Wang, W., Shan, Y., Wang, C., Zhu, M., La, Q., Zhong, Y., Xu, Y., Nan, P., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13257696
Wu, X., Li, X., Wang, W., Shan, Y., Wang, C., Zhu, M., La, Q., Zhong, Y., Xu, Y., Nan, P., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13257687
Wu, X., Li, X., Wang, W., Shan, Y., Wang, C., Zhu, M., La, Q., Zhong, Y., Xu, Y., Nan, P., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13257675
Wu, X., Li, X., Wang, W., Shan, Y., Wang, C., Zhu, M., La, Q., Zhong, Y., Xu, Y., Nan, P., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13257690
Wu, X., Li, X., Wang, W., Shan, Y., Wang, C., Zhu, M., La, Q., Zhong, Y., Xu, Y., Nan, P., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13257699
Muneer, A., Noor, M., Jamshed, S., Shahid, A., Anjum, A., Parveen, F., Rahman, A., & Ali, P. A. (2026) · medtigo Journal of Pharmacology · doi:10.63096/medtigo3061322
Linares, R., Rosas, G., Vieyra, E., Chaparro, A., Espinoza, J. A., Ramírez, D. A., Silva, C., Rosas, P., Macías, V.-M., & Morales‐Ledesma, L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27114715
Seo, Y., & Woo, J. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27167111
- Authors
- Funk, R. S., Singh, R. K., Winefield, R. D., Kandel, S. E., Ruisinger, J. F., Moriarty, P. M., & Backes, J. M.
- Affiliations
- University of Kansas Medical Center (US)
- Corresponding author
- Funk, Ryan S.
- ORCID
- Venue
- Journal of Dietary Supplements
- Publisher
- Informa UK Limited
- Published
- 2017-08-09
- Volume
- 15
- Issue
- 3
- Pages
- 343-351
- ISSN
- 1939-0211 (ISSN-L)
- 1939-022X
- PMC
- PMC5807210
- OpenAlex
- W2744322969
- Semantic Scholar
- af180c5d8623ed9103dcf95e98e847137a83cfc9
- Cited by
- 29
- References
- 23
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 3 · 2020: 10 · 2019: 1
- FWCI
- 2.51
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Dietary Supplements (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of General Medical Sciences (P20GM103549, P30GM118247)
- Topics
- Health Sciences › Medicine › Pharmacology › Berberine and alkaloids research
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pharmaceutical Quality and Counterfeiting
- Health Sciences › Medicine › Complementary and alternative medicine › Complementary and Alternative Medicine Studies
- Keywords
- berberine, dietary supplements, isoquinoline alkaloids, type 2 diabetes, dyslipidemia
- MeSH terms
- Hypolipidemic Agents, Berberine, Capsules, Chromatography, High Pressure Liquid, Costs and Cost Analysis, Food Inspection, Food Labeling, Hypoglycemic Agents, Pharmacopoeias as Topic, Plant Extracts, United States, Reproducibility of Results, Molecular Structure, Dietary Supplements, Internet, Spectrometry, Mass, Electrospray Ionization, Berberis, Hydrastis, Tandem Mass Spectrometry, Food Quality
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
